Edgewise Therapeutics, Inc. quarterly report, Q1 FY2023

Business context and reporting period

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare muscle disorders. This unaudited Form 10-Q covers the quarter ended March 31, 2023; comparisons are with the three months ended March 31, 2022 unless otherwise stated. The company has no approved products, has generated no revenue and has never been profitable.

• Lead candidate EDG-5506 is in Phase 2 trials for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
• EDG-7500 is in nonclinical development for hypertrophic cardiomyopathy; the company planned to begin a Phase 1 trial in late 2023.
• The EDG-003 cardiovascular program remains at the discovery stage.

Financial performance and liquidity

• R&D and G&A expense rose by $8.8 million and $2.1 million, respectively. The filing attributes increases principally to expanded clinical activity and manufacturing for EDG-5506, increased personnel and stock-based compensation, and development of EDG-7500 and EDG-003.
• Higher interest income, primarily reflecting higher rates on investments, partly offset increased operating expenses. The company reported no product revenue, so commercial margins are not applicable.
• Cash and cash equivalents were $48.2 million and available-for-sale marketable securities were $279.7 million at quarter-end. Operating cash outflow increased year over year; investing cash inflow largely reflected maturities of securities, not cash generated by operations.
• Total assets were $346.4 million, total liabilities $17.6 million, and stockholders’ equity $328.8 million at March 31, 2023. Accumulated deficit was $167.4 million. The filing reports operating lease liabilities of $5.6 million, including $0.8 million current; it discloses no borrowing debt.
• Management believes existing cash, cash equivalents and marketable securities will fund operations and liquidity needs through at least the next 12 months from issuance of the financial statements. The company says it will need substantial additional capital over time; no shares had been sold under its $125 million at-the-market program as of March 31, 2023.

Material changes versus the prior comparable period

• Net loss increased by $8.2 million, as operating expenses rose by $10.9 million, partly offset by a $2.7 million increase in interest income.
• EDG-5506 clinical program expense increased $3.2 million, including activity in the Canyon, Lynx and Dune studies that was not active in the comparable 2022 period, as well as higher manufacturing costs.
• Cash used in operations increased by $10.3 million. Quarter-end cash, cash equivalents and marketable securities declined approximately $24.0 million from December 31, 2022.
• Other comprehensive income included a $1.1 million unrealized gain on available-for-sale securities, versus a $1.4 million unrealized loss in Q1 2022. The filing attributes unrealized portfolio losses at March 31, 2023 primarily to interest-rate and market credit-spread changes, not increased credit risk in specific securities.
• The company added 9,624 square feet of office space through a February 2023 lease modification. Property and equipment purchases were $4.4 million in Q1 2023, compared with $0.4 million in Q1 2022.

Outlook, commentary, risks and contingencies

• Management expects expenses to increase as clinical trials advance, manufacturing and platform development continue, and the company hires staff. It cautions that development timing and costs are uncertain and that it may need additional financing; equity financing could dilute stockholders, while debt could impose restrictive terms.
• Key execution risks include clinical safety and efficacy, trial enrollment and timing, regulatory decisions, manufacturing supply and third-party performance, competition, intellectual-property protection, and the company’s ability to secure capital. The company has no committed external source of funding.
• The filing discusses the March 2023 Silicon Valley Bank receivership and the possibility that banking-sector disruption could impair access to uninsured or excess-insurance-limit funds. The company says certain operating accounts were maintained at SVB; the filing does not provide a clear value for any funds affected or lost.
• Other monitored risks include inflation, tighter credit markets, the Russia-Ukraine conflict, cybersecurity and COVID-19-related disruption. The company noted prior CRO cybersecurity incidents, including an ongoing investigation of a 2023 cyberattack at a CRO.
• EDG-5506 had previously shown dose-limiting somnolence at 135 mg in a single-ascending-dose trial; dizziness and somnolence were reported as generally mild and transient in prior studies. Earlier positive topline and interim results are not guarantees of later trial outcomes.
• The company reported no material legal proceedings pending or threatened and no material changes to critical accounting estimates. Management concluded disclosure controls were effective as of March 31, 2023, with no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

1. Progress, enrollment, safety and efficacy results for the EDG-5506 BMD and DMD Phase 2 trials, and whether announced interim findings are confirmed by complete data.
2. Whether the planned EDG-7500 Phase 1 start in late 2023 occurred, and how EDG-003 research is progressing.
3. Quarterly operating cash burn, investment maturities and the assumptions behind management’s stated runway of at least 12 months.
4. Any new financing, including ATM sales or other equity or debt issuance, and the resulting dilution or restrictions.
5. Any material impact from banking-sector access risk, CRO cybersecurity incidents, clinical supply constraints or trial delays.